Уноси

• Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

  B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021

• Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

  B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021

• The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future (2021-06)

  B. Godman, M. Haque, T. Leong, E. Allocati, S. Kumar, S. Islam, J. Charan, F. Akter, A. Kurdi, C. Vassalo, M. Abu Bakar, S. Abdur Rahim, N. Sultana, F. Deeba, H. Khan, M. Alam, I. Jahan, Z. Kamal, H. Hasan, M. E-Murshid, S. Nahar, M. Haque, S. Dutta, J. Pallavi Abhayanand, R. Jeet Kaur, G. Rwegerera, R. Nascimento, I. Godoi, M. Irfan, A. Amu, P. Matowa, J. Acolatse, R. Incoom, I. Sefah, J. Acharya, S. Opanga, L. Njeri, D. Kimonge, H. Kwon, S. Bae, K. Khuan, A. Abu Bakar, I. Sani, T. Khan, S. Hussain, Z. Saleem, O. Malande, T. Piloya-Were, R. Gambogi, C. Hernandez Ortiz, L. Alutuli, A. Kalungia, I. Hoxha, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, M. Wladysiuk, J. Rutkowski, I. Mardare, J. Furst, S. McTaggart, S. MacBride-Stewart, C. Pontes, C. Zara, E. Tagoa, R. Banzi, J. Wale, M. Jakovljevic, The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future, Frontiers in public health, Vol. 9, pp. 1 - 21, Jun, 2021

• Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

  B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauremann, M. Hinteregger, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, J. Slaby, R. Nejezchlebova, I. Selke Krulichova, O. Laius, G. Selke, I. Langer, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, P. Vella Bonanno, J. Rutkowski, S. Ingeberg, O. Melien, I. Mardare, J. Furst, S. McBride-Stewart, C. Holmes, C. Pontes, C. Zara, M. Turu Pedrola, M. Hoffman, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark, Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications, BioMed Research International, Vol. 2021, No. Article ID 99961, pp. 1 - 16, Oct, 2021

• Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

  B. Godman, B. Tubić, E. Allocati, M. Wladysiuk, S. McTaggart, A. Kurdi, M. Haque, S. McBride-Stewart, F. Kalemeera, A. Massele, I. Hoxha, V. Marković Peković, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, P. Vella Bonanno, J. Rutkowski, I. Mardare, J. Furst, C. Pontes, C. Zara, M. Turu Pedrola, F. Akter, H. Kwon, A. Martin, R. Banzi, J. Wale, J. Gulbinovic, Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues, Journal of Applied Pharmaceutical Science, Vol. 12, No. 3, pp. 055 - 072, Mar, 2022

• Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)

  A. Pisana, B. Wettermark, A. Kurdi, Б. Тубић, C. Pontes, C. Zara, E. Van Ganse, G. Petrova, I. Mardare, J. Furst, M. Roig-Izquierdo, O. Melien, P. Vella Bonanno, R. Banzi, V. Marković Peković, Z. Mitkova, B. Godman, Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries, Frontiers in Pharmacology, No. 873556, pp. 1 - 16, Jun, 2022